The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Open accessAbstract
Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production of hormones and vasoactive peptides. Because of their perceived rarity, NETs have not historically been a focus of rigorous clinical research. However, the diagnosed incidence of NETs has been increasing, and the estimated prevalence in the United States exceeds 100,000 individuals. The recent completion of several phase III studies, including those evaluating octreotide, sunitinib, and everolimus, has demonstrated that rigorous evaluation of novel agents in this disease is both feasible and can lead to practice-changing outcomes. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trials planning meeting to identify key unmet needs, develop appropriate study end points, standardize clinical trial inclusion criteria, and formulate priorities for future NET studies for the US cooperative group program. Emphasis was placed on the development of well-designed clinical trials with clearly defined efficacy criteria. Key recommendations include the evaluation of pancreatic NET separately from NETs of other sites and the exclusion of patients with poorly differentiated histologies from trials focused on low-grade histologies. Studies evaluating novel agents for the control of hormonal syndromes should avoid somatostatin analog washout periods when possible and should include quality-of-life end points. Because of the observed long survival after progression of many patients, progression-free survival is recommended as a feasible and relevant primary end point for both phase III studies and phase II studies where a delay in progression is expected in the absence of radiologic responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Self-citationA 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Rindi, G., Klöppel, G., Couvelard, A., Komminoth, P., Körner, M., Lopes, J. M., McNicol, A.-M., Nilsson, O., Perren, A., Scarpa, A., et al. (2007) · Virchows Archiv · doi:10.1007/s00428-007-0452-1 · Cited by 955
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Self-citationYao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
Self-citationActivity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Self-citationKouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Self-citationFynn, R. W. (1959) · PubMed · Cited by 502
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Broglio, K. R., & Berry, D. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp369 · Cited by 491
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008215730767 · Cited by 455
Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Self-citationClinical Relevance of MGMT in the Treatment of Cancer
Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 428
Kennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., et al. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e4557 · Cited by 424
Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S.-C. J., Hess, K., Ng, C., Abbruzzese, J. L., & Ajani, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6374 · Cited by 414
Self-citationKulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S., Ryan, D. P., Enzinger, P. C., Meyerhardt, J. A., Clark, J. W., Stuart, K., Fuchs, C. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1476 · Cited by 381
Self-citation90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306
Self-citationTumor Markers in Neuroendocrine Tumors
Eriksson, B., Öberg, K., & Stridsberg, M. (2000) · Digestion · doi:10.1159/000051853 · Cited by 299
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases
King, J., Quinn, R., Glenn, D. M., Janssen, J., Tong, D., Liaw, W., & Morris, D. L. (2008) · Cancer · doi:10.1002/cncr.23685 · Cited by 284
Hepatic surgery for metastases from neuroendocrine tumors
Sarmiento, J. M., & Que, F. G. (2003) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(02)00076-5 · Cited by 227
Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Valkema, R., Bakker, W. H., Kooij, P. P., Visser, T. J., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100502 · Cited by 226
Le Treut, Y. P., Grégoire, E., Belghiti, J., Boillot, O., Soubrane, O., Mantion, G., Cherqui, D., Castaing, D., Ruszniewski, P., Wolf, P., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02233.x · Cited by 189
Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., & Mooney, M. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1711 · Cited by 177
Genetics of neuroendocrine and carcinoid tumours.
Leotlela, P. D., Jauch, A., Holtgreve-Grez, H., & Thakker, R. V. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100437 · Cited by 162
Pavel, M. E., Baudin, É., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx193 · Cited by 128
Self-citationKulke, M. H., Freed, E., Chiang, D. Y., Philips, J., Zahrieh, D., Glickman, J. N., & Shivdasani, R. A. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20561 · Cited by 126
Self-citationImaging appearances of metastases from neuroendocrine tumours of the pancreas
Debray, M., Geoffroy, O., Laissy, J., Lebtahi, R., Silbermann-Hoffman, O., Henry–Feugeas, M.-C., Cadiot, G., Mignon, M., & Schouman‐Claeys, E. (2001) · British Journal of Radiology · doi:10.1259/bjr.74.887.741065 · Cited by 100
Peptide receptor radionuclide therapy
Teunissen, J. J. M., Kwekkeboom, D. J., de Jong, M., Esser, J.-P., Valkema, R., & Krenning, E. P. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.04.001 · Cited by 93
Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
Sargent, D. J., & Hayes, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8064 · Cited by 83
Kvols, L. K., Wiedenmann, B. J., Öberg, K., Glusman, J. E., O’Dorisio, T. M., de Herder, W., Gao, B., Arnold, R., & Anthony, L. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4082 · Cited by 54
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Self-citationNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Self-citation
Metadata
- Authors
- Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., Van Cutsem, E., Pingpank, J., Oberg, K., Cohen, S. J., Posner, M. C., & Yao, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 934-943
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167834420
- Cited by
- 304
- References
- 36
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.